Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 26;11(10):1442. doi: 10.3390/cancers11101442

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

LCC-09 treatment concomitantly suppresses multiple oncogenic and stemness markers as well as aldehyde dehydrogenase (ALDH) activity in GBM cells. LCC-09 (A) inhibited the ability of TMZ-resistant CD133⁺ U87MG and D54MG cells to form neurospheres dose-dependently, (B) reduced the ALDH activity of TMZ-resistant CD133⁺ U87MG and D54MG cells, and (C) suppressed the expression level of DRD4, β-catenin, Akt, mTOR, Erk1/2, EZH2, c-Myc, and CDK6 proteins in the LCC-09-treated TMZ-resistant CD133⁺ U87MG and D54MG cells compared to their vehicle-treated counterparts. β-actin served as loading control. * p < 0.05, ** p < 0.01, *** p < 0.001; data represent the mean ± SD of experiments performed 4 times in triplicates.